GordonPH: Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis, 2013; 4:295–310.
2.
BrooksBR, ThistedRA, AppelSH, et al.: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology, 2004; 63:1364–1370.
3.
MillerA, PrattH, SchifferRB: Pseudobulbar affect: The spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother, 2011; 11:1077–1088.
4.
JenkinsTM, HollingerH, McDermottCJ: The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol, 2014; 27:524–531.
5.
American Academy of Neurology: AAN summary of evidence-based guideline for clinicians: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment. AAN, 2009. www.aan.com/Guidelines/Home/GetGuidelineContent/377. (Last accessed May1, 2015.)
6.
AshworthNL, SatkunamLE, DeforgeD: Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev, 2012; 2:CD004156.
7.
BorasioGD, VoltzR, MillerRG: Palliative care in amyotrophic lateral sclerosis. Neurol Clin, 2001; 19:829–847.
8.
BrettschneiderJ, KurentJ, LudolphA: Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev, 2013; 6:CD005226.
9.
OliverD: The quality of care and symptom control: The effects on the terminal phase of ALS/MND. J Neurol Sci, 1996; 139:134–136.
10.
ClemensKE, KlaschikE: Morphine in the management of dyspnoea in ALS: A pilot study. Eur J Neurol, 2008; 15:445–450.
11.
HallenbeckJ: Pathophysiologies of dyspnea explained: Why might opioids relieve dyspnea and not hasten death?. J Palliat Med, 2012; 15:848–853.
